ABSTRACT
OBJECTIVE: We studied whether the institution of basal-bolus therapy immediately after diagnosis improved glycemic control in the first year after diagnosis for children with newly diagnosed type 1 diabetes mellitus. METHODS: We reviewed the charts of 459 children > or =6 years of age who were diagnosed as having type 1 diabetes between July 1, 2002, and June 30, 2006 (212 treated with basal-bolus therapy and 247 treated with a more-conventional neutral protamine Hagedorn regimen). We abstracted data obtained at diagnosis and at quarterly clinic visits and compared groups by using repeated-measures, mixed-linear model analysis. We also reviewed the records of 198 children with preexisting type 1 diabetes mellitus of >1-year duration who changed from the neutral protamine Hagedorn regimen to a basal-bolus regimen during the review period. RESULTS: Glargine-treated subjects with newly diagnosed diabetes had lower hemoglobin A1c levels at 3, 6, 9, and 12 months after diagnosis than did neutral protamine Hagedorn-treated subjects (average hemoglobin A1c levels of 7.05% with glargine and 7.63% with neutral protamine Hagedorn, estimated across months 3, 6, 9, and 12, according to repeated-measures models adjusted for age at diagnosis and baseline hemoglobin A1c levels; treatment difference: 0.58%). Children with long-standing diabetes had no clinically important changes in their hemoglobin A1c levels in the first year after changing regimens. CONCLUSION: The institution of basal-bolus therapy with insulin glargine at the time of diagnosis of type 1 diabetes was associated with improved glycemic control, in comparison with more-conventional neutral protamine Hagedorn regimens, during the first year after diagnosis.
Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Hypoglycemic Agents/administration & dosage , Insulin, Isophane/administration & dosage , Insulin/analogs & derivatives , Blood Glucose/analysis , Child , Diabetes Mellitus, Type 1/physiopathology , Glycated Hemoglobin , Humans , Insulin/administration & dosage , Insulin Glargine , Insulin, Long-Acting , Patient Compliance , Retrospective Studies , Treatment OutcomeABSTRACT
OBJECTIVE: Diabetes camp has become a common part of medical practice worldwide. Although patients' knowledge and self-management of diabetes may improve after camp, improved glycated hemoglobin A1c (HbA1c) levels have not been consistently demonstrated. RESEARCH DESIGN AND METHODS: We performed a retrospective study of medical records at the Children's Medical Center Dallas Endocrinology Center for adolescents with type 1 diabetes aged 12-18 yr. We compared patients who did (n = 77) or did not (n = 106) attend Camp Sweeney, a regional 20-d diabetes camp. Some patients (n = 82) and their parents also completed measures of adherence, depression, and quality of life. RESULTS: HbA1c decreased over time in patients who attended diabetes camp {mean [+/-standard deviation (SD)] at baseline, (T1) = 8.6% (+/-1.8%) and at follow-up, (T2) = 8.3% (+/-1.6%)}, whereas it increased in those who did not attend [mean (+/-SD) at T1 = 8.4% (+/-2.1%) and at T2 = 8.9% (+/-2.3%)] (p < 0.005). Seven months after camp (T3), there were still significant differences in HbA1c between the camp and control groups (p = 0.04), with the difference because of persistent improvement for girls but not for boys. Patients' adherence (p < 0.05) and adjustment (p < 0.05) improved by parental report in those who attended camp; parents of patients who did not attend did not report the change. CONCLUSIONS: Attending Camp Sweeney is associated with improved glycemic control and parent-reported adherence and adjustment in adolescents with type 1 diabetes. Additional studies are needed to determine whether these findings can be generalized to other diabetes camps.
